Carbocisteine for fatty liver disease: safety and benefit study
Part of Digestive system clinical trials.
This study tests a medicine called carbocisteine to see if it can help treat nonalcoholic fatty liver disease (NAFLD). If you have a fatty liver and no other liver or kidney conditions, this trial may explore whether this drug is safe and effective for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of fatty liver, confirmed by an ultrasound of your belly.
- You cannot be pregnant or nursing.
- You should not be a heavy drinker (more than 2 drinks daily for men, 1 for women).
- Your fatty liver must not be caused by other liver diseases like hepatitis or autoimmune disease.
- You should not have chronic kidney disease or parathyroid problems, and must not be allergic to carbocisteine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a structured lifestyle program—focused on healthy living and resistance exercise—can help prevent fatty liver disease and heart-related problems. It may be helpful if you have early or mild fatty liver changes or risk factors, even if you also have gallstones.
This study looks at what drives non-alcoholic fatty liver disease and how it affects the body, including immune-related changes. You may be invited if you have confirmed fatty liver disease or, alternatively, if you are a healthy person with no liver disease.
This trial tests whether a medicine called erdosteine can help treat non-alcoholic fatty liver disease (a condition where extra fat builds up in the liver, not caused by alcohol). It is for adults who have fatty liver confirmed by ultrasound and who do not have other serious health problems.
This study tests whether a medicine called cilostazol can help treat nonalcoholic fatty liver disease. It is for adults who have fatty liver seen on an ultrasound and do not have other liver problems.
This trial tests if adding TENS (a gentle electrical stimulation therapy) to a Mediterranean-style eating plan helps control appetite and improve liver health in people with non-alcoholic fatty liver disease (NAFLD).
This trial studies how the liver processes fat in people with non-alcoholic fatty liver disease (NAFLD). It uses MRI scans to look at liver metabolism, which may help doctors understand the disease better and find new treatments.
Hear when a new Non-Alcoholic Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.